The Oncology Institute (TOI) is expanding its partnership with Helios Clinical Research to bring clinical trials to more community oncology settings nationwide. Building on a successful collaboration in Florida, this expansion aims to integrate research more deeply into TOI’s patient care model. This initiative is driven by TOI’s commitment to providing cutting-edge cancer care and improving patient access to innovative therapies.
This expansion is crucial for advancing community oncology. It offers patients broader access to clinical trials, often limited to larger academic centers. By integrating research into routine care, TOI can offer novel treatments to a wider patient population, potentially improving outcomes and quality of life for individuals who might not otherwise have these options. The collaboration also benefits pharmaceutical sponsors by providing access to a larger, more diverse patient pool, which can accelerate trial timelines and lead to more robust research results.
Helios Clinical Research will provide operational and logistical support for the trials, including regulatory management, patient recruitment, and overall trial oversight. This allows TOI clinicians to focus on patient care while still participating in groundbreaking research. The partnership also emphasizes enrolling diverse and underrepresented patient populations, a critical aspect of ensuring equitable access to advanced cancer therapies and addressing health disparities.
This expansion signifies a broader trend of decentralizing clinical trials and bringing them closer to patients in community settings. It positions TOI as a leader in integrating research and care, potentially attracting both patients and clinicians interested in participating in cutting-edge oncology advancements. It could also serve as a model for other community oncology practices, ultimately accelerating the development and delivery of innovative cancer therapies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
